A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients
Status:
Recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
This study is a multicenter randomized double-blinded controlled phase 2 study evaluating the
efficacy and safety of the anti-CMV drug valganciclovir vs placebo as add-on therapy in
patients with glioblastoma. Valganciclovir is approved for treatment of cytomegalovirus (CMV)
infections, but may also have anti-tumoral effects. Current evidence imply that most
glioblastomas are CMV positive and that the virus can affect tumor aggressiveness.
Phase:
Phase 2
Details
Lead Sponsor:
Cecilia Soderberg-Naucler
Collaborators:
Karolinska Institutet Karolinska University Hospital